Publikationen in Zusammenarbeit mit Forschern von Academic Medical Center (32)

2024

  1. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

  2. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

  3. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study

    Cancer, Vol. 130, Núm. 6, pp. 886-900

  4. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

  5. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

    Blood Advances, Vol. 8, Núm. 1, pp. 194-206

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  2. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

    Advances in Therapy, Vol. 40, Núm. 5, pp. 2412-2425

  3. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

    Leukemia and Lymphoma

  4. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma

    Cancer, Vol. 129, Núm. 13, pp. 2035-2046

  5. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

    Blood

2022

  1. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: Final results of the SYNTAX II study

    European Heart Journal, Vol. 43, Núm. 13, pp. 1307-1316

  2. High frequency of central nervous system involvement in transformed Waldenstrom € macroglobulinemia

    Blood Advances

  3. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

    Blood cancer journal, Vol. 12, Núm. 2, pp. 32

  4. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

  5. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

    Blood Advances

  6. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2021

  1. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

    BMC Infectious Diseases, Vol. 21, Núm. 1

  2. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options

    Blood Reviews, Vol. 49

  3. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

    Blood Cancer Journal, Vol. 11, Núm. 2

  4. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

    The Lancet, Vol. 398, Núm. 10301, pp. 665-674